

Noelia Casares

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9008747/publications.pdf>

Version: 2024-02-01

70
papers

9,132
citations

159585

30
h-index

114465

63
g-index

70
all docs

70
docs citations

70
times ranked

14991
citing authors

#	ARTICLE	IF	CITATIONS
1	TCR-induced FOXP3 expression by CD8+ T cells impairs their anti-tumor activity. <i>Cancer Letters</i> , 2022, 528, 45-58.	7.2	7
2	Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy. <i>OncolImmunology</i> , 2022, 11, 2070337.	4.6	9
3	Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	2
4	Impact of tumor microenvironment on adoptive T cell transfer activity. <i>International Review of Cell and Molecular Biology</i> , 2022, , 1-31.	3.2	8
5	Intratumoral STING Agonist Injection Combined with Irreversible Electroporation Delays Tumor Growth in a Model of Hepatocarcinoma. <i>BioMed Research International</i> , 2021, 2021, 1-9.	1.9	8
6	Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses. <i>Emerging Microbes and Infections</i> , 2021, 10, 1931-1946.	6.5	11
7	Searching for Peptide Inhibitors of T Regulatory Cell Activity by Targeting Specific Domains of FOXP3 Transcription Factor. <i>Biomedicines</i> , 2021, 9, 197.	3.2	3
8	Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model. <i>Journal of Nanobiotechnology</i> , 2021, 19, 102.	9.1	27
9	Olfactory Characterization and Training in Older Adults: Protocol Study. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 757081.	3.4	4
10	Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens. , 2020, 8, e000704.		8
11	Cellular cytotoxicity is a form of immunogenic cell death. , 2020, 8, e000325.		61
12	Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression. <i>Nature Medicine</i> , 2019, 25, 1073-1081.	30.7	125
13	FOXP3 Inhibitory Peptide P60 Increases Efficacy of Cytokine-induced Killer Cells Against Renal and Pancreatic Cancer Cells. <i>Anticancer Research</i> , 2019, 39, 5369-5374.	1.1	5
14	Treatment of Experimental Autoimmune Encephalomyelitis by Sustained Delivery of Low-Dose IFN- β . <i>Journal of Immunology</i> , 2019, 203, 696-704.	0.8	6
15	Therapeutic Effect of Irreversible Electroporation in Combination with Poly-ICLC Adjuvant in Preclinical Models of Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 1098-1105.	0.5	15
16	PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas. <i>Blood</i> , 2019, 133, 2401-2412.	1.4	54
17	Genetic Modification of CD8+ T Cells to Express EGFR: Potential Application for Adoptive T Cell Therapies. <i>Frontiers in Immunology</i> , 2019, 10, 2990.	4.8	14
18	A new immune-nanoplatform for promoting adaptive antitumor immune response. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 17, 13-25.	3.3	17

#	ARTICLE	IF	CITATIONS
19	The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer. <i>Oncolimmunology</i> , 2018, 7, e1409321.	4.6	15
20	Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasms. <i>Haematologica</i> , 2018, 103, 1065-1072.	3.5	10
21	Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virusâ€œDerived Vectors Fosters Dendritic Cellâ€œMediated T-cell Cross-Priming. <i>Cancer Research</i> , 2018, 78, 6643-6654.	0.9	60
22	Immunomodulatory Properties of Carvone Inhalation and Its Effects on Contextual Fear Memory in Mice. <i>Frontiers in Immunology</i> , 2018, 9, 68.	4.8	14
23	Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy. <i>Cancer Research</i> , 2017, 77, 3672-3684.	0.9	99
24	Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. <i>Nature Communications</i> , 2017, 8, 15424.	12.8	109
25	Therapeutic blockade of Foxp3 in experimental breast cancer models. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 393-405.	2.5	21
26	Reversal of Diabetes in NOD Mice by Clinical-Grade Proinsulin and IL-10â€œSecreting <i>Lactococcus lactis</i> in Combination With Low-Dose Anti-CD3 Depends on the Induction of Foxp3-Positive T Cells. <i>Diabetes</i> , 2017, 66, 448-459.	0.6	57
27	Relevance of CD6-Mediated Interactions in the Regulation of Peripheral T-Cell Responses and Tolerance. <i>Frontiers in Immunology</i> , 2017, 8, 594.	4.8	12
28	Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor. <i>Oncotarget</i> , 2017, 8, 71709-71724.	1.8	27
29	MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells. <i>Oncotarget</i> , 2016, 7, 23182-23196.	1.8	58
30	Evaluation of a Salmonella Strain Lacking the Secondary Messenger C-di-GMP and RpoS as a Live Oral Vaccine. <i>PLoS ONE</i> , 2016, 11, e0161216.	2.5	13
31	Targeting inhibition of Foxp3 by a CD28 2â€²-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy. <i>Biomaterials</i> , 2016, 91, 73-80.	11.4	43
32	A core of kinase-regulated interactomes defines the neoplastic MDSC lineage. <i>Oncotarget</i> , 2015, 6, 27160-27175.	1.8	51
33	P0262 : Inhibition of regulatory T cells using the FOXP3-inhibitory peptide P60 improves antitumoural effect of a vaccination with mAFP-expressing DC in subcutaneous and orthotopic murine HCC model. <i>Journal of Hepatology</i> , 2015, 62, S404-S405.	3.7	0
34	Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation. <i>Journal of Immunology</i> , 2015, 195, 3180-3189.	0.8	44
35	1163 EDA-STREPTAVIDIN FUSION PROTEIN CONJUGATED TO BIOTINYLATED HCV-NS3 PROTEIN INDUCES STRONG T CELL IMMUNE RESPONSES AGAINST NS3. <i>Journal of Hepatology</i> , 2013, 58, S473.	3.7	1
36	Searching for the Achilles Heel of FOXP3. <i>Frontiers in Oncology</i> , 2013, 3, 294.	2.8	22

#	ARTICLE	IF	CITATIONS
37	A Fusion Protein between Streptavidin and the Endogenous TLR4 Ligand EDA Targets Biotinylated Antigens to Dendritic Cells and Induces T Cell Responses <i>In Vivo</i> . <i>BioMed Research International</i> , 2013, 2013, 1-9.	1.9	15
38	Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses. <i>Vaccine</i> , 2012, 30, 2848-2858.	3.8	21
39	Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin. <i>International Journal of Cancer</i> , 2012, 131, 641-651.	5.1	34
40	Contribution of IL-17 α -producing $\gamma\delta$ T cells to the efficacy of anticancer chemotherapy. <i>Journal of Experimental Medicine</i> , 2011, 208, 491-503.	8.5	303
41	Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection. <i>Journal of Hepatology</i> , 2011, 54, 422-431.	3.7	68
42	A Peptide Inhibitor of FOXP3 Impairs Regulatory T Cell Activity and Improves Vaccine Efficacy in Mice. <i>Journal of Immunology</i> , 2010, 185, 5150-5159.	0.8	97
43	In vivo depletion of T lymphocyte-specific transcription factors by RNA interference. <i>Cell Cycle</i> , 2010, 9, 2902-2907.	2.6	5
44	Tumor therapy in mice by using a tumor antigen linked to modulin peptides from <i>Staphylococcus epidermidis</i> . <i>Vaccine</i> , 2010, 28, 7146-7154.	3.8	8
45	685 IMMUNIZATION AGAINST HEPATITIS C VIRUS USING A PEPTIDE FROM NS3 PROTEIN LINKED TO MODULINS DERIVED FROM STAPHYLOCOCCUS EPIDERMIDIS. <i>Journal of Hepatology</i> , 2010, 52, S267.	3.7	0
46	Peptide inhibitors of transforming growth factor β enhance the efficacy of antitumor immunotherapy. <i>International Journal of Cancer</i> , 2009, 125, 2614-2623.	5.1	62
47	Induction of Multiepitopic and Long-Lasting Immune Responses Against Tumour Antigens by Immunization with Peptides, DNA and Recombinant Adenoviruses Expressing Minigenes. <i>Scandinavian Journal of Immunology</i> , 2009, 69, 80-89.	2.7	12
48	Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein. <i>Journal of Hepatology</i> , 2009, 51, 520-527.	3.7	21
49	883 VACCINATION AGAINST HEPATITIS C VIRUS WITH A RECOMBINANT FUSION PROTEIN CONTAINING THE EXTRA DOMAIN A FROM FIBRONECTIN AND THE HEPATITIS C VIRUS NS3 PROTEIN. <i>Journal of Hepatology</i> , 2009, 50, S321.	3.7	0
50	612 THE EXTRA DOMAIN A FROM FIBRONECTIN (EDA) IMPROVES IMMUNOGENICITY OF NS3 PROTEIN IN A SEMLIKI FOREST VIRUS (SFV)-BASED VACCINE AGAINST HEPATITIS C. <i>Journal of Hepatology</i> , 2008, 48, S228.	3.7	0
51	In Vitro and In Vivo Down-Regulation of Regulatory T Cell Activity with a Peptide Inhibitor of TGF β 1. <i>Journal of Immunology</i> , 2008, 181, 126-135.	0.8	63
52	The Extra Domain A from Fibronectin Targets Antigens to TLR4-Expressing Cells and Induces Cytotoxic T Cell Responses <i>In Vivo</i> . <i>Journal of Immunology</i> , 2007, 178, 748-756.	0.8	89
53	Upregulation of Indoleamine 2,3-Dioxygenase in Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2007, 81, 3662-3666.	3.4	116
54	Calreticulin exposure dictates the immunogenicity of cancer cell death. <i>Nature Medicine</i> , 2007, 13, 54-61.	30.7	2,580

#	ARTICLE	IF	CITATIONS
55	531 Expression of T regulatory cell-associated genes in the liver of patients with hepatitis C: Implications on viral chronification. <i>Journal of Hepatology</i> , 2006, 44, S198.	3.7	0
56	A novel dendritic cell subset involved in tumor immunosurveillance. <i>Nature Medicine</i> , 2006, 12, 214-219.	30.7	377
57	Apoptosis regulation in tetraploid cancer cells. <i>EMBO Journal</i> , 2006, 25, 2584-2595.	7.8	180
58	Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. <i>Journal of Experimental Medicine</i> , 2005, 202, 1691-1701.	8.5	1,224
59	Inhibition of Macroautophagy Triggers Apoptosis. <i>Molecular and Cellular Biology</i> , 2005, 25, 1025-1040.	2.3	1,533
60	Increased Immunogenicity of Colon Cancer Cells by Selective Depletion of Cytochrome c. <i>Cancer Research</i> , 2004, 64, 2705-2711.	0.9	17
61	AIF deficiency compromises oxidative phosphorylation. <i>EMBO Journal</i> , 2004, 23, 4679-4689.	7.8	576
62	Immune Response Against Dying Tumor Cells. <i>Advances in Immunology</i> , 2004, 84, 131-179.	2.2	104
63	A recombinant adenovirus encoding hepatitis C virus core and E1 proteins protects mice against cytokine-induced liver damage. <i>Hepatology</i> , 2003, 37, 461-470.	7.3	23
64	CD4 ⁺ /CD25 ⁺ Regulatory Cells Inhibit Activation of Tumor-Primed CD4 ⁺ T Cells with IFN- β -Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination. <i>Journal of Immunology</i> , 2003, 171, 5931-5939.	0.8	186
65	Engineering Th determinants for efficient priming of humoral and cytotoxic T cell responses. <i>International Immunology</i> , 2003, 15, 691-699.	4.0	2
66	Abnormal Priming of CD4 ⁺ T Cells by Dendritic Cells Expressing Hepatitis C Virus Core and E1 Proteins. <i>Journal of Virology</i> , 2002, 76, 5062-5070.	3.4	141
67	Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus. <i>Vaccine</i> , 2002, 21, 202-210.	3.8	57
68	Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. <i>European Journal of Immunology</i> , 2001, 31, 1780-1789.	2.9	77
69	Th1 but not Th0 cell help is efficient to induce cytotoxic T lymphocytes by immunization with short synthetic peptides. <i>International Immunology</i> , 1999, 11, 2025-2034.	4.0	21
70	Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. <i>Hepatology</i> , 1998, 28, 815-822.	7.3	80